NFATC4 and cardiac hypertrophy: Since the dysregulation of NFATC4 has been linked to disorders such as breast and ovarian cancer as well as cardiac hypertrophy (47–49), the development of blockers specifically targeting the Cn/NFATC4 interaction could be used as a therapeutic strategy for multiple diseases.